Trump administration announces funding for PTSD research on ibogaineWIRED investigation examines Jensen Huang's comments on defining women's power in techWalmart launches early Black Friday promotions on select giftsMint Mobile offers $500 discount on select new phones for new customers signing up for a yearRussia and Iran criticize U.S. Caspian task force amid reports of joint sanction evasion effortsNewly elected US lawmakers pose for traditional group photo at Capitol ahead of 120th Congress openingUS existing home sales drop to lowest monthly level in yearsPro-Palestine philanthropist faces US extradition hearing in SpainLewisham Islamic Centre criticizes charity watchdog over warning on Palestine commentsSenegalese wrestlers succeed in beach wrestling at Dakar Youth OlympicsUS nonprofits file lawsuit seeking pause on advanced AI model trainingDemocrats convene in Denver to discuss party direction after midterm victoriesUS releases report on $12bn from Venezuelan oil, mineral resourcesPope Leo XIV urges Catholic Church to address clergy sexual abuseShooting near White House results in death, suspect later found dead
Back to event

Schedules of Controlled Substances: Placement of Oveporexton in Schedule IV

By Justice Department, Drug Enforcement Administration · Nov 11, 2026, 11:00 PM CST

Read full article at Federal Register
On August 5, 2026, the United States Food and Drug Administration (FDA) approved a new drug application for Orzeyful (oveporexton) for the treatment of narcolepsy type 1 in adults. The Department of Health and Human Services (HHS) provided the Drug Enforcement Administration (DEA) with a scheduling recommendation to place oveporexton, chemically known as N-[(2S,3R)-2-[[3-(3,5- difluorophenyl)-2-fl

Excerpt shown under fair-use limits. Full text remains with the original publisher.

Layer 1 · Claims & fact checks

AI analysis

Layer 2 · Biblical perspective

Biblical interpretation
INSUFFICIENT CONTEXT
Read the biblical analysis

Layer 3 · Reporting analysis

AI analysis

Formal languageThe use of formal legal phrasing emphasizes authority and procedural legitimacy.

Technical detailProviding the full chemical name signals precision and aims to inform a specialized audience.

Scope definitionThe clause broadens the regulatory coverage, indicating an intent to preemptively include all possible variants.

Context

AI analysis

Missing context

The excerpt does not explain the criteria used by the DEA to determine Schedule IV placement, any public comment period, or the potential impact on patients, prescribers, or law‑enforcement. It also omits background on the Improving Regulatory Transparency for New Medical Therapies Act that amended the CSA.

Important context

The scheduling decision follows an FDA approval for a new narcolepsy treatment and a recommendation from HHS, indicating coordination among federal agencies. The rule is described as an "interim final rule," suggesting it may be subject to later amendment.

Opinion vs. reporting

AI analysis

The excerpt presents factual statements about agency actions without offering opinion or analysis; it is purely reporting of regulatory events.